Shareholders in Twist Bioscience (NASDAQ:TWST) Have Lost 84%, as Stock Drops 9.6% This Past Week
Shareholders in Twist Bioscience (NASDAQ:TWST) Have Lost 84%, as Stock Drops 9.6% This Past Week
As an investor, mistakes are inevitable. But really bad investments should be rare. So spare a thought for the long term shareholders of Twist Bioscience Corporation (NASDAQ:TWST); the share price is down a whopping 84% in the last three years. That would be a disturbing experience. The more recent news is of little comfort, with the share price down 57% in a year. Shareholders have had an even rougher run lately, with the share price down 23% in the last 90 days. While a drop like that is definitely a body blow, money isn't as important as health and happiness.
作为投资者,错误是不可避免的。但是真正糟糕的投资应该很少见。因此,请多考虑一下Twist Bioscience Corporation(纳斯达克股票代码:TWST)的长期股东;在过去三年中,股价下跌了84%。那将是一种令人不安的经历。最近的消息并不令人满意,股价在一年内下跌了57%。股东们最近的表现更加艰难,在过去的90天中,股价下跌了23%。虽然这样的下降绝对是沉重的打击,但金钱并不像健康和幸福那么重要。
Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.
鉴于过去一周对股东来说很艰难,让我们调查一下基本面,看看我们能学到什么。
See our latest analysis for Twist Bioscience
查看我们对 Twist Bioscience 的最新分析
Given that Twist Bioscience didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.
鉴于Twist Bioscience在过去十二个月中没有盈利,我们将专注于收入增长,以快速了解其业务发展。无利可图公司的股东通常预计收入将强劲增长。一些公司愿意推迟盈利以更快地增长收入,但在这种情况下,人们确实预计收入将保持良好的增长。
In the last three years, Twist Bioscience saw its revenue grow by 36% per year, compound. That is faster than most pre-profit companies. So why has the share priced crashed 23% per year, in the same time? You'd want to take a close look at the balance sheet, as well as the losses. Sometimes fast revenue growth doesn't lead to profits. Unless the balance sheet is strong, the company might have to raise capital.
在过去的三年中,Twist Bioscience的收入每年增长36%。这比大多数盈利前公司都要快。那么,为什么股价同时每年暴跌23%呢?你需要仔细看看资产负债表以及亏损。有时,快速的收入增长并不能带来利润。除非资产负债表强劲,否则公司可能不得不筹集资金。
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
下图显示了收入和收入随时间推移的跟踪情况(如果您点击图片,可以看到更多细节)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231112/0-5ccc91e53261ef5b363e3d8b911680bd-0-e87de321270843a169fa311331d1a89c.png/big)
We consider it positive that insiders have made significant purchases in the last year. Even so, future earnings will be far more important to whether current shareholders make money. This free report showing analyst forecasts should help you form a view on Twist Bioscience
我们认为,去年内部人士进行了大量收购,这是积极的。即便如此,未来的收益对于当前股东是否赚钱将更为重要。这份显示分析师预测的免费报告应该可以帮助你对Twist Bioscience形成看法
A Different Perspective
不同的视角
Investors in Twist Bioscience had a tough year, with a total loss of 57%, against a market gain of about 10%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Twist Bioscience you should know about.
Twist Bioscience的投资者经历了艰难的一年,总亏损了57%,而市场涨幅约为10%。但是,请记住,即使是最好的股票有时也会在十二个月内表现逊于市场。令人遗憾的是,去年的业绩结束了糟糕的表现,股东们在五年内每年面临7%的总亏损。总的来说,长期股价疲软可能是一个坏兆头,尽管逆势投资者可能希望研究该股,希望出现转机。尽管值得考虑市场状况可能对股价产生的不同影响,但还有其他因素更为重要。例如,以风险为例。每家公司都有它们,我们已经发现了Twist Bioscience的1个警告信号,你应该知道。
Twist Bioscience is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Twist Bioscience并不是业内人士唯一买入的股票。对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。